Worldwide clinical practices in perioperative antibiotic therapy for lung transplantation.


Journal

BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563

Informations de publication

Date de publication:
29 Apr 2020
Historique:
received: 22 12 2019
accepted: 15 04 2020
entrez: 1 5 2020
pubmed: 1 5 2020
medline: 26 1 2021
Statut: epublish

Résumé

Infection is the most common cause of mortality within the first year after lung transplantation (LTx). The management of perioperative antibiotic therapy is a major issue, but little is known about worldwide practices. We sent by email a survey dealing with 5 daily clinical vignettes concerning perioperative antibiotic therapy to 180 LTx centers around the world. The invitation and a weekly reminder were sent to lung transplant specialists for a single consensus answer per center during a 3-month period. We received a total of 99 responses from 24 countries, mostly from Western Europe (n = 46) and the USA (n = 34). Systematic screening for bronchial recipient colonization before LTx was mostly performed with sputum samples (72%), regardless of the underlying lung disease. In recipients without colonization, antibiotics with activity against gram-negative bacteria resistant strains (piperacillin / tazobactam, cefepime, ceftazidime, carbapenems) were reported in 72% of the centers, and antibiotics with activity against methicillin-resistant Staphylococcus aureus (mainly vancomycin) were reported in 38% of the centers. For these recipients, the duration of antibiotics reported was 7 days (33%) or less (26%) or stopped when cultures of donor and recipients were reported negatives (12%). In recipients with previous colonization, antibiotics were adapted to the susceptibility of the most resistant strain and given for at least 14 days (67%). Practices vary widely around the world, but resistant bacterial strains are mostly targeted even if no colonization occurs. The antibiotic duration reported was longer for colonized recipients.

Sections du résumé

BACKGROUND BACKGROUND
Infection is the most common cause of mortality within the first year after lung transplantation (LTx). The management of perioperative antibiotic therapy is a major issue, but little is known about worldwide practices.
METHODS METHODS
We sent by email a survey dealing with 5 daily clinical vignettes concerning perioperative antibiotic therapy to 180 LTx centers around the world. The invitation and a weekly reminder were sent to lung transplant specialists for a single consensus answer per center during a 3-month period.
RESULTS RESULTS
We received a total of 99 responses from 24 countries, mostly from Western Europe (n = 46) and the USA (n = 34). Systematic screening for bronchial recipient colonization before LTx was mostly performed with sputum samples (72%), regardless of the underlying lung disease. In recipients without colonization, antibiotics with activity against gram-negative bacteria resistant strains (piperacillin / tazobactam, cefepime, ceftazidime, carbapenems) were reported in 72% of the centers, and antibiotics with activity against methicillin-resistant Staphylococcus aureus (mainly vancomycin) were reported in 38% of the centers. For these recipients, the duration of antibiotics reported was 7 days (33%) or less (26%) or stopped when cultures of donor and recipients were reported negatives (12%). In recipients with previous colonization, antibiotics were adapted to the susceptibility of the most resistant strain and given for at least 14 days (67%).
CONCLUSION CONCLUSIONS
Practices vary widely around the world, but resistant bacterial strains are mostly targeted even if no colonization occurs. The antibiotic duration reported was longer for colonized recipients.

Identifiants

pubmed: 32349719
doi: 10.1186/s12890-020-1151-9
pii: 10.1186/s12890-020-1151-9
pmc: PMC7191774
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

109

Références

J Heart Lung Transplant. 2019 May;38(5):545-552
pubmed: 30733155
J Heart Transplant. 1990 Sep-Oct;9(5):502-8; discussion 508-9
pubmed: 2231088
J Heart Lung Transplant. 2013 Nov;32(11):1065-72
pubmed: 23953918
Clin Microbiol Infect. 2014 Sep;20 Suppl 7:89-101
pubmed: 24707957
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
BMC Pulm Med. 2018 May 22;18(1):86
pubmed: 29788939
Ann Thorac Surg. 2019 Apr;107(4):e239-e241
pubmed: 30316849
Clin Infect Dis. 2001 Jul 1;33 Suppl 1:S26-31
pubmed: 11389519
Transplant Rev (Orlando). 2018 Jan;32(1):36-57
pubmed: 28811074
J Heart Lung Transplant. 2015 Jan;34(1):1-15
pubmed: 25085497
J Heart Lung Transplant. 2010 Dec;29(12):1395-404
pubmed: 20810293
Chest. 2016 Jul;150(1):219-25
pubmed: 27212132
Surg Today. 2019 Mar;49(3):254-260
pubmed: 30368607
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Eur Respir J. 2015 Mar;45(3):726-37
pubmed: 25359351
J Heart Lung Transplant. 2007 Sep;26(9):890-7
pubmed: 17845927
BMC Pulm Med. 2018 Mar 5;18(1):43
pubmed: 29506501
J Heart Lung Transplant. 2006 Jan;25(1):99-105
pubmed: 16399537
J Infect. 2020 Feb;80(2):190-196
pubmed: 31843689
Ann Pharmacother. 2017 Mar;51(3):185-193
pubmed: 27838680
Eur J Cardiothorac Surg. 2018 Mar 1;53(3):603-609
pubmed: 29048473
Thorax. 2008 Aug;63(8):732-7
pubmed: 18408050
Clin Chest Med. 2016 Mar;37(1):59-67
pubmed: 26857768
Interact Cardiovasc Thorac Surg. 2011 Dec;13(6):631-4
pubmed: 21920934
Clin Transplant. 2016 Jul;30(7):767-73
pubmed: 27091109
N Engl J Med. 2007 Dec 20;357(25):2601-14
pubmed: 18094380
Transpl Infect Dis. 2019 Apr;21(2):e13034
pubmed: 30548546
Am J Health Syst Pharm. 2013 Feb 1;70(3):195-283
pubmed: 23327981
Respirology. 2016 May;21(4):590-9
pubmed: 26852737
Crit Care Med. 2012 Jan;40(1):162-8
pubmed: 21926613
Am J Transplant. 2006 Jan;6(1):178-82
pubmed: 16433772
Clin Transplant. 2014 Jan;28(1):27-36
pubmed: 24410732
Am J Transplant. 2008 May;8(5):1025-30
pubmed: 18318775
Ann Thorac Med. 2016 Jan-Mar;11(1):55-9
pubmed: 26933458
J Heart Lung Transplant. 2015 Oct;34(10):1264-77
pubmed: 26454740
Clin Transplant. 2019 Sep;33(9):e13513
pubmed: 30817030
J Transplant. 2012;2012:135738
pubmed: 22848792
Am J Transplant. 2007 Aug;7(8):1989-96
pubmed: 17617864
Clin Transplant. 2013 Mar-Apr;27(2):303-10
pubmed: 23316931
BMC Infect Dis. 2012 Dec 26;12:375
pubmed: 23267668
Transplantation. 2015 May;99(5):1078-83
pubmed: 25757211

Auteurs

Benjamin Coiffard (B)

Department of Respiratory Medicine and Lung Transplantation, Aix Marseille University, APHM, Hôpital Nord, 13015, Marseille, France. bcoiffard.aphm@gmail.com.
Aix Marseille University, APHM, Hôpital Nord, Intensive Care Unit, Marseille, France. bcoiffard.aphm@gmail.com.
Aix Marseille University, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France. bcoiffard.aphm@gmail.com.

Eloi Prud'Homme (E)

Aix Marseille University, APHM, Hôpital Nord, Intensive Care Unit, Marseille, France.

Sami Hraiech (S)

Aix Marseille University, APHM, Hôpital Nord, Intensive Care Unit, Marseille, France.

Nadim Cassir (N)

Aix Marseille University, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Jérôme Le Pavec (J)

Department of Cardio-Thoracic Surgery and Heart-Lung Transplantation, Hôpital Marie-Lannelongue, Le Plessis-Robinson, France.

Romain Kessler (R)

Department of Respiratory Medicine and Lung Transplantation, Federation of Translational Medicine of Strasbourg (FMTS), Nouvel Hôpital Civil, Strasbourg, France.

Federica Meloni (F)

Department of Medical Sciences and Infective Diseases, Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Marc Leone (M)

Aix Marseille University, APHM, Hôpital Nord, Department of Thoracic Surgery, Marseille, France.

Pascal Alexandre Thomas (PA)

Aix Marseille University, APHM, Hôpital Nord, Department of Anesthesiology, Marseille, France.

Martine Reynaud-Gaubert (M)

Department of Respiratory Medicine and Lung Transplantation, Aix Marseille University, APHM, Hôpital Nord, 13015, Marseille, France.

Laurent Papazian (L)

Aix Marseille University, APHM, Hôpital Nord, Intensive Care Unit, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH